Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lantana Consulting Group, East Thetford, Vermont, USA.
Transfusion. 2023 Oct;63 Suppl 4(Suppl 4):S19-S42. doi: 10.1111/trf.17509. Epub 2023 Sep 13.
The Department of Health and Human Services' National Blood Collection and Utilization Survey (NBCUS) has been conducted biennially since 1997. Data are used to estimate national blood collection and use. Supplemental data from the 2021 NBCUS not presented elsewhere are presented here.
Data on survey participation, donor characteristics, blood component cost, transfusion-associated adverse reactions, and implementation of blood safety measures, including pathogen-reduction of platelets, during 2021, were analyzed. Comparisons are made to 2019 survey data where available (2013-2019 for survey participation).
During 2021, there were 11,507,000 successful blood donations in the United States, a 4.8% increase from 2019. Persons aged 45-64 years accounted for 42% of all successful blood donations. Donations by persons aged 65 years and older increased by 40.7%, while donations among minorities and donors aged <25 years decreased. From 2019 to 2021, the median price hospitals paid per unit of leukoreduced red blood cells, leukoreduced and pathogen-reduced apheresis platelets, and fresh frozen plasma increased. The largest increase in price per unit of blood component in 2021 was for leukoreduced apheresis platelets, which increased by ~$51. Between 2019 and 2021, the proportion of transfusing facilities reporting use of pathogen-reduced platelets increased, from 13% to 60%. Transfusion-related adverse reactions declined slightly between 2019 and 2021, although the rate of transfusion-transmitted bacterial infections remained unchanged.
During 2021, blood donations increased nationally, although donations from those aged <25 years and minorities declined. The prices hospitals paid for most blood products increased, as did the use of pathogen-reduced platelets.
自 1997 年以来，美国卫生与公众服务部（HHS）每两年进行一次国家血液采集和利用调查（NBCUS）。数据用于估计国家血液采集和使用情况。此处呈现的是 2021 年 NBCUS 中其他地方未呈现的补充数据。
分析了 2021 年调查参与情况、供者特征、血液成分成本、输血相关不良反应以及血液安全措施实施情况的数据，包括血小板病原体减少。在可用情况下（2013-2019 年用于调查参与），与 2019 年调查数据进行了比较。
2021 年，美国有 1150.7 万次成功献血，比 2019 年增长 4.8%。45-64 岁的人群占所有成功献血者的 42%。65 岁及以上人群的献血量增加了 40.7%，而少数族裔和<25 岁的献血者的献血量则有所下降。2019 年至 2021 年，医院每单位去白细胞红细胞、去白细胞和病原体减少的单采血小板以及新鲜冰冻血浆的支付价格中位数均有所上升。2021 年血液成分单位价格涨幅最大的是去白细胞单采血小板，增加了约 51 美元。2019 年至 2021 年，报告使用病原体减少血小板的输血机构比例从 13%增加到 60%。尽管输血传播细菌感染率保持不变，但 2019 年至 2021 年期间，输血相关不良反应略有下降。
2021 年，全国献血量增加，尽管<25 岁和少数族裔的献血量下降。医院支付的大多数血液产品价格上涨，病原体减少血小板的使用也增加。
